Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.
JAMA Netw Open. 2021 Oct 1;4(10):e2128998. doi: 10.1001/jamanetworkopen.2021.28998.
Transient elevations of blood glucose levels are common in hospitalized older adults with diabetes and may lead clinicians to discharge patients with more intensive diabetes medications than they were using before hospitalization.
To investigate outcomes associated with intensification of outpatient diabetes medications at discharge.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study assessed patients 65 years and older with diabetes not taking insulin who were hospitalized in the Veterans Health Administration Health System between January 1, 2011, and September 28, 2016, for common medical conditions. Data analysis was performed from January 1, 2020, to March 31, 2021.
Discharge with intensified diabetes medications, defined as filling a prescription at hospital discharge for a new or higher-dose medication than was being used before hospitalization. Propensity scores were used to construct a matched cohort of patients who did and did not receive diabetes medication intensifications.
Coprimary outcomes of severe hypoglycemia and severe hyperglycemia were assessed at 30 and 365 days using competing risk regressions. Secondary outcomes included all-cause readmissions, mortality, change in hemoglobin A1c (HbA1c) level, and persistent use of intensified medications at 1 year after discharge.
The propensity-matched cohort included 5296 older adults with diabetes (mean [SD] age, 73.7 [7.7] years; 5212 [98.4%] male; and 867 [16.4%] Black, 47 [0.9%] Hispanic, 4138 [78.1%] White), equally split between those who did and did not receive diabetes medication intensifications at hospital discharge. Within 30 days, patients who received medication intensifications had a higher risk of severe hypoglycemia (hazard ratio [HR], 2.17; 95% CI, 1.10-4.28), no difference in risk of severe hyperglycemia (HR, 1.00; 95% CI, 0.33-3.08), and a lower risk of death (HR, 0.55; 95% CI, 0.33-0.92). At 1 year, no differences were found in the risk of severe hypoglycemia events, severe hyperglycemia events, or death and no difference in change in HbA1c level was found among those who did vs did not receive intensifications (mean postdischarge HbA1c, 7.72% vs 7.70%; difference-in-differences, 0.02%; 95% CI, -0.12% to 0.16%). At 1 year, 48.0% (591 of 1231) of new oral diabetes medications and 38.5% (548 of 1423) of new insulin prescriptions filled at discharge were no longer being filled.
In this national cohort study, among older adults hospitalized for common medical conditions, discharge with intensified diabetes medications was associated with an increased short-term risk of severe hypoglycemia events but was not associated with reduced severe hyperglycemia events or improve HbA1c control. These findings indicate that short-term hospitalization may not be an effective time to intervene in long-term diabetes management.
患有糖尿病的住院老年患者血糖水平短暂升高很常见,这可能导致临床医生为患者开出比住院前更强化的糖尿病药物。
研究出院时强化门诊糖尿病药物治疗的结果。
设计、地点和参与者:本回顾性队列研究评估了 2011 年 1 月 1 日至 2016 年 9 月 28 日期间在退伍军人健康管理局医疗系统中因常见医疗状况住院的年龄在 65 岁及以上且未使用胰岛素的糖尿病患者。数据分析于 2020 年 1 月 1 日至 2021 年 3 月 31 日进行。
出院时强化糖尿病药物治疗,定义为在出院时开处方使用新的或更高剂量的药物,而不是在住院前使用的药物。使用倾向评分构建了一个接受和未接受糖尿病药物强化治疗的患者匹配队列。
使用竞争风险回归在 30 天和 365 天评估严重低血糖和严重高血糖的主要结局。次要结局包括所有原因再入院、死亡率、血红蛋白 A1c(HbA1c)水平变化以及出院后 1 年内持续使用强化药物。
倾向评分匹配队列包括 5296 名患有糖尿病的老年患者(平均[标准差]年龄,73.7[7.7]岁;5212[98.4%]为男性;867[16.4%]为黑人,47[0.9%]为西班牙裔,4138[78.1%]为白人),分为接受和未接受出院时糖尿病药物强化治疗的两组,比例相等。在 30 天内,接受药物强化治疗的患者发生严重低血糖的风险更高(风险比[HR],2.17;95%置信区间[CI],1.10-4.28),严重高血糖的风险无差异(HR,1.00;95%CI,0.33-3.08),死亡率较低(HR,0.55;95%CI,0.33-0.92)。在 1 年时,接受强化治疗与未接受强化治疗的患者在严重低血糖事件、严重高血糖事件或死亡风险方面没有差异,并且在接受强化治疗与未接受强化治疗的患者中,HbA1c 水平的变化也没有差异(出院后平均 HbA1c,7.72%比 7.70%;差异-差异,0.02%;95%CI,-0.12%至 0.16%)。在 1 年时,新口服糖尿病药物处方中 48.0%(591/1231)和新胰岛素处方中 38.5%(548/1423)不再继续使用。
在这项全国性队列研究中,在因常见医疗状况住院的老年患者中,强化糖尿病药物治疗与短期严重低血糖事件风险增加相关,但与严重高血糖事件风险降低或 HbA1c 控制改善无关。这些发现表明,短期住院可能不是干预长期糖尿病管理的有效时间。